Abstract
Background:
High expression of lncRNA LINC00525 is associated with the progressive development of various cancers, including lung adenocarcinoma (LUAD). LncRNAs play regulatory roles in transcription and gene expression.Objectives:
This study aimed to investigate, for the first time, the effect of LINC00525 knockdown on the transcriptome and signaling pathways of A549 LUAD cells.Methods:
Differentially expressed genes (DEGs) were identified after LINC00525 silencing in A549 cells using the gene expression profile GSE171460. R packages were employed to identify enriched pathways. Hub genes were identified using a PPI network based on the STRING database. The RNAInter and TRRUST databases were used to predict transcription factors (TFs) that interact with LINC00525 and regulate DEGs.Results:
LINC00525 knockdown significantly altered the expression of approximately 3,093 genes. The most significantly enriched pathways were the cell cycle and cytokine signaling pathways. All identified hub genes were upregulated, many of which were related to the cytokine signaling pathway, including STAT1, IL6, ISG15, IRF1, IRF7, IFIH1, and IFIT3. According to the GEPIA database, decreased LINC00525 expression showed a positive correlation with increased expression of the hub genes IL6, DDX58, IFIH1, OAS1, OAS2, and IFIT3, supporting the findings of this study. Based on the transcriptional regulatory network, some TFs of DEGs and hub genes may interact with LINC00525.Conclusions:
These findings support the positive association between LINC00525 overexpression and tumor growth. LINC00525 may serve as a potential therapeutic target for LUAD. Further research is needed to explore other functional mechanisms of LINC00525.Keywords
Cell Cycle Cytokine Signaling LINC00525 Lung Adenocarcinoma Transcription
1. Background
Lung adenocarcinoma (LUAD) accounts for the majority of non-small-cell lung cancer (NSCLC), one of the leading causes of cancer morbidity worldwide. As with other cancers, the exact molecular mechanisms of LUAD have not been fully understood (1). Recently, long non-coding RNAs (lncRNAs) have emerged as important targets in cancer research. Long non-coding RNAs are a class of regulatory RNAs that can function as oncogenes or tumor suppressors and serve as diagnostic or prognostic cancer biomarkers (2).
Long non-coding RNAs regulate the proliferation, invasion, and chemoresistance of cancer cells, primarily through their involvement in gene expression regulation. Gene expression regulation is a complex process with multiple control levels, and lncRNAs play a role in influencing it (3). Long non-coding RNAs can modify chromatin by interacting with chromatin modifiers or directly binding to DNA. Additionally, they can interact with transcription factors (TFs) and RNA polymerases, affecting their functions. In the cytoplasm, lncRNAs exert post-transcriptional, translational, and post-translational regulation on gene expression. Their regulatory mechanisms include interacting with mRNAs, sponging microRNAs, interacting with the translation machinery, and binding to peptides (4, 5).
As a result, the dysregulation of lncRNAs can lead to disruptions in the expression levels of various genes. Gene expression dysregulation is a common molecular feature of cancers and can be utilized for cancer diagnosis and treatment (6).
Long non-coding RNAs can have both oncogenic and tumor-suppressive effects in cancer (7). LINC00525 is an upregulated and oncogenic lncRNA in LUAD and other cancers, such as colorectal cancer and spinal chordoma (8-10). LINC00525 is associated with high rates of cell proliferation and metastasis in these cancers (9). Several molecular mechanisms have been proposed for LINC00525, including reducing the transcription and stability of p21 (a cell cycle blocker) in LUAD and sponging miR-31-5p and miR-125a-5p in spinal chordoma (9, 10). In colorectal cancer, overexpression of LINC00525 leads to apoptosis resistance and cell cycle progression through the suppression of tumor suppressor genes P15, P21, P27, and KLF2 (8). Additionally, LINC00525 overexpression promotes metastasis, stemness, and chemoresistance in cancer cells (11, 12). Therefore, understanding the downstream regulatory networks of LINC00525 is crucial, and targeting LINC00525 could be a promising strategy in cancer therapy.
2. Objectives
This study utilized in silico data to identify genes whose expression was altered following LINC00525 knockdown in a LUAD cell line. The gene expression profile GSE171460 was used to determine the differentially expressed genes (DEGs) after silencing LINC00525 in LUAD A549 cells. The aim was to identify genes related to LINC00525 in LUAD cells and explore potential molecular mechanisms that could be targeted in therapeutic approaches. Additionally, the study investigated related signaling pathways and their effects on cellular processes. The correlation between LINC00525 and the expression of hub genes, as well as the regulatory network of related TFs, was also evaluated.
3. Methods
3.1. Datasets and Data Processing
Using the UALCAN database, the expression of LINC00525 was analyzed across various cancer types, including LUAD. RNA-seq LUAD data were obtained from TCGA using R software, comprising 541 cases and 59 matching adjacent normal tissues. The ROC curve and expression level of LINC00525 were examined using GraphPad Prism 9. The GSE171460 data package, containing microarray data from human LUAD A549 cells, was downloaded from the GEO database. In this dataset, LINC00525 was downregulated using siRNA in LUAD cells, while scramble siRNA was transfected into A549 cells as a negative control. Differentially expressed genes between the control and LINC00525 knockdown groups were identified using GEO2R online tools and the R program.
3.2. Pathway Enrichment Analysis
The R package enrichR was used for Reactome_2022 analysis of DEGs in A549 cells. The plotEnrich package was employed to visualize the results, with an adjusted P-value of ≤ 0.05.
3.3. Hub Genes Identification
The STRING database was used to construct a protein-protein interaction (PPI) network of DEGs, with interactions having scores > 0.4 considered statistically significant. The results were visualized using CytoScape (version 3.6.1) software. To identify the hub genes, CytoHubba, a plug-in of CytoScape, was employed, utilizing the degree algorithm for selection. The correlation between the expression of hub genes and LINC00525 was evaluated using the GEPIA database.
3.4. Prediction of Transcription Factors Which Can Be Interacted with LINC00525
The RNAInter database was used to identify TFs that interact with LINC00525. The TRRUST database was employed to predict target genes regulated by the identified TFs (adjusted P-value ≤ 0.05). The overlap between the predicted target genes and the differentially expressed mRNAs in A549 cells was analyzed using a Venn diagram.
4. Results
4.1. LINC00525 Was Considerably Upregulated in Lung Adenocarcinoma
Analysis of RNA-seq datasets from the TCGA revealed that LINC00525 was expressed at significantly higher levels in tumors compared to normal tissues (Figure 1A). ROC curve analysis further confirmed the potential of this lncRNA to serve as a diagnostic biomarker in LUAD (Figure 1B). According to a pan-cancer investigation using the UALCAN database, LINC00525 expression was upregulated in various cancer types, particularly in LUAD (Figure 1C).
Expression pattern and diagnostic value of LINC00525. A, significant expression difference (P-value cutoff = 0.05) of LINC00525 in tumor compared to normal tissue according to UALCAN; B, the ROC curve of LINC00525 in LUAD. AUC was 0.91 with 95% CI. Red represents the sensitivity curve, and black indicates the identification line. The X axis shows the false positive rate, presented as “1-Specificity”. The Y axis indicates the true positive rate, shown as “Sensitivity”; C, overexpression of LINC00525 was shown in several cancers, most notably LUAD tissue according to UALCAN.
4.2. Changes of mRNA Profile After the Silencing of LINC00525
A total of 3,093 differentially expressed mRNAs (|log2FC| ≥ 0.1 and adjusted P-value ≤ 0.05) were identified in the GSE171460 dataset. Among these, 1,360 DEGs were upregulated, and 1,733 were downregulated in the lncRNA downregulated cells compared to control LUAD cells (Figure 2A and B). The MX1 gene, with a logFC = 4.94, was the most upregulated, while the LOC102724250 gene, with a logFC = -0.9, was the most downregulated. After integrating the DEGs, genes with |log2FC| ≥ 0.5 were selected for further analysis.
Differential expression of mRNAs after LINC00525 knockdown. A, volcano plot; and B, mean-difference plot of GSE171460 (downregulated LINC00525 cancer cells vs control cancer cells)
4.3. Pathway Enrichment Analysis, Protein-Protein Interaction Network Construction of Differentially Expressed Genes, and Selection of Hub Genes
In the Reactome_2022 analysis, the most significantly enriched pathway for DEGs was the cell cycle (Figure 3). In addition to the cell cycle, cytokine signaling was also among the significantly enriched pathways following LINC00525 silencing. The protein interaction network of the DEGs was constructed using STRING. Based on the Degree method of CytoHubba in Cytoscape, 11 hub genes were identified from the STRING data (Table 1).
Pathway enrichment analysis, protein-protein interaction (PPI) network construction of differentially expressed genes (DEGs). A, significant pathways related to DEGs; and B, PPI network for the DEGs of A549 cells (downregulated LINC00525 compared to control) in Cytoscape, genes with more interactions are depicted with the high intensity of red color.
Hub Genes According to in the CytoHubba (Degree Algorithm) of Cytoscape.
| Rank | Gene Name | Score | logFC (in LINC00525 Downregulated Compared to Control) |
|---|---|---|---|
| 1 | STAT1 (signal transducer and activator of transcription 1) | 92 | 1.31 |
| 2 | IL6 (interleukin 6) | 90 | 1.34 |
| 3 | IRF1 (interferon regulatory factor 1) | 84 | 0.7 |
| 4 | DDX58 (DEAD (Asp-Glu-Ala-Asp) box polypeptide 58) | 80 | 2.82 |
| 5 | IRF7 (interferon regulatory factor 7) | 77 | 2.08 |
| 6 | IFIH1 (interferon induced with helicase C domain1) | 74 | 0.5 |
| 7 | MX1 (MX dynamin like GTPase 1) | 73 | 4.94 |
| 8 | OAS2 (2'-5'-oligoadenylate synthetase 2) | 71 | 1.88 |
| 8 | ISG15 (interferon-stimulated gene 15) | 71 | 3.42 |
| 10 | OAS1 (2'-5'-oligoadenylate synthetase 1) | 68 | 1.83 |
| 10 | IFIT3 (interferon-induced protein with tetratricopeptide repeats 3) | 68 | 3.46 |
4.3.1. Evaluation of Hub Gene in the GEPIA Database
According to Pearson correlation analysis using the GEPIA online tool, mRNA expression levels of STAT1, ISG15, and OAS1 were significantly increased, while IL6 expression was decreased in LUAD tumor samples compared to normal samples (Figure 4A). Additionally, the GEPIA database showed that decreased expression of LINC00525 correlated with increased expression of IL6, DDX58, IFIH1, OAS1, OAS2, and IFIT3, which aligns with the results of this study (Figure 4B).
Evaluation of hub genes in GEPIA online website. A, differential expression of STAT1, ISG15, OAS1, and IL6 was significant in LUAD tumors compared to adjacent normal tissues according to the GEPIA; B, the expression of LINC00525 significantly is related to IL6, DDX58, IFIH1, OAS1, OAS2, and IFIT3.
4.4. Possible Effect of LINC00525 on mRNAs Through Interaction with Transcription Factors
LncRNAs can activate or suppress the expression of downstream target genes through interactions with TFs. Based on the RNAInter database, 43 TFs that interact with LINC00525 were identified (score ≥ 0.3). The targets of these TFs were then identified using the TRRUST database. LINC00525 can influence the expression levels of these TF targets. A Venn diagram revealed 257 overlapping genes between DEGs and TF targets (Figure 5A). Notably, 11 TFs were also among the genes modified after LINC00525 knockdown, with some sharing common targets with DEGs (Figure 5B and C). Additionally, Figure 5D illustrates the TFs of hub genes that interact with LINC00525.
TFs influenced by LINC00525 and their regulatory networks based on RNA Inter and TRRUST databases. A, 257 DEGs were among the targets of affected TFs by LINC00525; B, 11 transcription factors (TFs) were identified as differentially expressed genes (DEGs); C, target DEGs that can be regulated by differentially expressed TFs. KDM5B gene did not exist in TRRUST database and FOXP1 has no common target genes with DEGs. Upregulated genes were written in red and downregulated ones in blue. Nods in red represent upregulated TFs and nodes in blue represent downregulated TFs; D, hub genes’ TFs which have interaction with LINC00525. Node in blue represents downregulated TF and white nodes represent unchanged TFs. Upregulated hub genes are written in red.
5. Discussion
Cell cycle progression has been reported as one tumorigenic function of overexpressed LINC00525 in LUAD (9). High expression of LINC00525 also leads to increased expression of cancer stem cell markers and chemoresistance in colorectal cancer cell lines (11). Moreover, the oncogenic role of LINC00525 has been documented in other cancers. For instance, LINC00525 promoted tumorigenesis and metastasis in spinal chordoma cell lines, while its inhibition enhanced apoptosis (12). LINC00525 has also been associated with survival and prognosis in oral squamous carcinoma, where its knockdown caused cell cycle arrest and apoptosis in carcinoma cells (12). The overexpression of LINC00525 across various cancers underscores its significance in tumorigenesis. Additionally, LINC00525 knockdown has been shown to induce various biological changes, including cell cycle arrest, apoptosis, drug sensitivity, and anti-invasive effects (8).
Given the regulatory effects of lncRNAs on gene expression, changes in lncRNA levels can modulate the transcriptome (7). Therefore, LINC00525 downregulation or upregulation can alter normal gene expression profiles, leading to changes in biological function and cell behavior (3). To date, several TFs, microRNAs, and mRNAs have been reported to be influenced by LINC00525. This study aimed to comprehensively assess the transcriptional changes in mRNAs following LINC00525 silencing in A549 LUAD cells. The silencing of LINC00525 caused significant changes in the mRNA profile of A549 LUAD cells, confirming the critical role of LINC00525 in gene expression regulation. As shown in Figure 2, LINC00525 silencing led to greater fold changes in upregulated genes compared to downregulated genes in A549 LUAD cells.
The cell cycle was identified as the primary cellular process associated with LINC00525 in A549 cells, as DEGs were significantly involved in this pathway. Accelerated cell division is a hallmark of cancer cells, often driven by mutations or disturbances in gene expression (13). Fang et al. demonstrated that the knockdown of LINC00525 led to G1 phase cell cycle arrest in A549 cells (9), and the data from this study further support this finding. Targeting cell cycle progression is a key therapeutic strategy for many anticancer drugs (13).
Cytokine signaling was another significantly enriched pathway among the DEGs. As shown in Figure 5, TFs of cytokine genes, including IRF1, IRF7, and IL6, could be influenced by LINC00525. Dysregulation of the cytokine regulatory network is a common feature in oncogenesis (14). Cytokines influence systemic inflammation and the immune tumor microenvironment, affecting various intracellular signaling pathways involved in tumor development. Cytokines can play both tumor-promoting and tumor-suppressing roles (15), and cytokine-based cancer therapies have been proposed (14). Dysregulation of cytokines is closely associated with cancer metastasis (16). In tumors, cytokines influence cancer cells and other components of the tumor microenvironment, leading to remodeling of the extracellular matrix, which can either support or hinder tumor growth and metastasis (17). This observation aligns with the positive association between LINC00525 overexpression and metastasis.
All identified hub genes were upregulated (Table 1), with many involved in the cytokine signaling pathway, including IL6, ISG15, IRF1, IRF7, IFIH1, and IFIT3. STAT1, another hub gene, belongs to the JAK-STAT pathway, a predominant signaling pathway activated by cytokines. These findings further confirm the role of the cytokine regulatory network in cell proliferation and tumor growth. Pearson correlation analysis also confirmed a correlation between the downregulation of LINC00525 and the upregulation of IL6, DDX58, IFIH1, OAS1, OAS2, and IFIT3. According to GEPIA, mRNA expression levels of STAT1, ISG15, and OAS1 were significantly increased, while IL6 expression was decreased in LUAD tumor samples compared to normal samples (Figure 4).
Silencing of LINC00525 in A549 cells led to the upregulation of all the aforementioned genes. STAT1, a transcription factor, plays key roles in various cellular biological processes, though its functions in tumor growth are not yet fully understood (18). One study reported that overexpressed STAT1 significantly inhibits the growth and invasion of lung cancer cells (19). Qu et al. demonstrated that upregulation of ISG15 inhibited tumor progression and migration of LUAD cells in both in vitro and in vivo experiments (20, 21). Although silencing LINC00525 led to a significant increase in OAS1, studies have shown that OAS1 promotes the proliferative activity of A549 LUAD cells (22, 23).
Regarding IL6, it has been reported that its activation of STAT3 results in cytotoxic CD8 T cell tumor infiltration, exerting a tumor-suppressing function. On the other hand, IL6 has also been found to promote tumors by activating cyclin D in LUAD (24). The tumor context plays a key role in determining IL6's functional direction, and it can have a preventive effect during the initiation of lung tumors (25). In this study, LINC00525 knockdown led to an increase in IL6 expression.
5.1. Conclusions
LINC00525 downregulation caused significant changes in the transcriptome of A549 LUAD cells. The evaluation of these altered genes provides insight into the molecular mechanisms by which LINC00525 promotes tumor growth and metastasis in LUAD. The most significantly enriched pathways for DEGs were the cell cycle and cytokine signaling pathways, both of which are commonly disrupted in cancers. Another key finding of this study was the identification of cytokine signaling-related hub genes, including STAT1, IL6, ISG15, IRF1, IRF7, IFIH1, and IFIT3. Further research is needed to explore other functional mechanisms of LINC00525, such as its interaction with differentially expressed microRNAs in A549 LUAD cells.
References
-
1.
O'Brien TD, Jia P, Aldrich MC, Zhao Z. Lung Cancer: One Disease or Many. Hum Hered. 2018;83(2):65-70. [PubMed ID: 29864749]. [PubMed Central ID: PMC6261707]. https://doi.org/10.1159/000488942.
-
2.
Gencel-Augusto J, Wu W, Bivona TG. Long Non-Coding RNAs as Emerging Targets in Lung Cancer. Cancers (Basel). 2023;15(12). [PubMed ID: 37370745]. [PubMed Central ID: PMC10295998]. https://doi.org/10.3390/cancers15123135.
-
3.
Engreitz JM, Haines JE, Perez EM, Munson G, Chen J, Kane M, et al. Local regulation of gene expression by lncRNA promoters, transcription and splicing. Nature. 2016;539(7629):452-5. [PubMed ID: 27783602]. [PubMed Central ID: PMC6853796]. https://doi.org/10.1038/nature20149.
-
4.
Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96-118. [PubMed ID: 33353982]. [PubMed Central ID: PMC7754182]. https://doi.org/10.1038/s41580-020-00315-9.
-
5.
Hu Q, Ma H, Chen H, Zhang Z, Xue Q. LncRNA in tumorigenesis of non-small-cell lung cancer: From bench to bedside. Cell Death Discov. 2022;8(1):359. [PubMed ID: 35963868]. [PubMed Central ID: PMC9376075]. https://doi.org/10.1038/s41420-022-01157-4.
-
6.
Ravindran U, Gunavathi C. A survey on gene expression data analysis using deep learning methods for cancer diagnosis. Prog Biophys Mol Biol. 2023;177:1-13. [PubMed ID: 35988771]. https://doi.org/10.1016/j.pbiomolbio.2022.08.004.
-
7.
Cao Z, Oyang L, Luo X, Xia L, Hu J, Lin J, et al. The roles of long non-coding RNAs in lung cancer. J Cancer. 2022;13(1):174-83. [PubMed ID: 34976181]. [PubMed Central ID: PMC8692699]. https://doi.org/10.7150/jca.65031.
-
8.
Zheng Q, Peng P. Long non-coding RNA Linc00525 is an unfavorable prognostic factor and regulates proliferation and apoptosis in colorectal cancer. Ann Oncol. 2019;30. https://doi.org/10.1093/annonc/mdz155.027.
-
9.
Fang P, Chen H, Ma Z, Han C, Yin W, Wang S, et al. LncRNA LINC00525 suppresses p21 expression via mRNA decay and triplex-mediated changes in chromatin structure in lung adenocarcinoma. Cancer Commun (Lond). 2021;41(7):596-614. [PubMed ID: 34105888]. [PubMed Central ID: PMC8286138]. https://doi.org/10.1002/cac2.12181.
-
10.
Gong F, Wang X, Sun Q, Su X, Hu X, Liu B. Long non-coding RNA LINC00525 interacts with miR-31-5p and miR-125a-5p to act as an oncogenic molecule in spinal chordoma. Biochem Biophys Res Commun. 2021;536:80-7. [PubMed ID: 33370717]. https://doi.org/10.1016/j.bbrc.2020.12.042.
-
11.
Wang S, Li J, Yang X. Long Non-Coding RNA LINC00525 Promotes the Stemness and Chemoresistance of Colorectal Cancer by Targeting miR-507/ELK3 Axis. Int J Stem Cells. 2019;12(2):347-59. [PubMed ID: 31242722]. [PubMed Central ID: PMC6657946]. https://doi.org/10.15283/ijsc19041.
-
12.
Du J, Su W, Li X, Zu T, Bai J, Zhang W, et al. LINC00525 promotes tumour growth and epithelial-mesenchymal transition as an oncogene in oral squamous cell carcinoma. Oral Dis. 2024;30(4):2051-62. [PubMed ID: 37183989]. https://doi.org/10.1111/odi.14613.
-
13.
Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23(1):74-88. [PubMed ID: 34508254]. https://doi.org/10.1038/s41580-021-00404-3.
-
14.
Stanilov N, Velikova T, Stanilova S. Navigating the Cytokine Seas: Targeting Cytokine Signaling Pathways in Cancer Therapy. Int J Mol Sci. 2024;25(2). [PubMed ID: 38256080]. [PubMed Central ID: PMC10815616]. https://doi.org/10.3390/ijms25021009.
-
15.
Kalvakolanu DV. Cytokine signaling in cancer: Novel players and pathways. Cytokine. 2017;89:1-3. https://doi.org/10.1016/j.cyto.2016.11.012.
-
16.
Yao M, Brummer G, Acevedo D, Cheng N. Cytokine Regulation of Metastasis and Tumorigenicity. Adv Cancer Res. 2016;132:265-367. [PubMed ID: 27613135]. https://doi.org/10.1016/bs.acr.2016.05.005.
-
17.
Mendez-Garcia LA, Nava-Castro KE, Ochoa-Mercado TL, Palacios-Arreola MI, Ruiz-Manzano RA, Segovia-Mendoza M, et al. Breast Cancer Metastasis: Are Cytokines Important Players During Its Development and Progression? J Interferon Cytokine Res. 2019;39(1):39-55. [PubMed ID: 30321090]. https://doi.org/10.1089/jir.2018.0024.
-
18.
Yang M, Chen H, Zhou L, Chen K, Su F. Expression profile and prognostic values of STAT family members in non-small cell lung cancer. Am J Transl Res. 2019;11(8):4866-80. [PubMed ID: 31497205]. [PubMed Central ID: PMC6731411].
-
19.
Chen J, Zhao J, Chen L, Dong N, Ying Z, Cai Z, et al. STAT1 modification improves therapeutic effects of interferons on lung cancer cells. J Transl Med. 2015;13:293. [PubMed ID: 26351076]. [PubMed Central ID: PMC4562290]. https://doi.org/10.1186/s12967-015-0656-0.
-
20.
Qu T, Zhang W, Yan C, Ren D, Wang Y, Guo Y, et al. ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma. J Transl Med. 2023;21(1):341. [PubMed ID: 37217923]. [PubMed Central ID: PMC10204161]. https://doi.org/10.1186/s12967-023-04135-1.
-
21.
Qu T, Zhang W, Qi L, Cao L, Liu C, Huang Q, et al. ISG15 induces ESRP1 to inhibit lung adenocarcinoma progression. Cell Death Dis. 2020;11(7):511. [PubMed ID: 32641707]. [PubMed Central ID: PMC7343783]. https://doi.org/10.1038/s41419-020-2706-7.
-
22.
Jiang S, Deng X, Luo M, Zhou L, Chai J, Tian C, et al. Pan-cancer analysis identified OAS1 as a potential prognostic biomarker for multiple tumor types. Front Oncol. 2023;13:1207081. [PubMed ID: 37746262]. [PubMed Central ID: PMC10511872]. https://doi.org/10.3389/fonc.2023.1207081.
-
23.
Luo D, Fang M, Shao L, Wang J, Liang Y, Chen M, et al. The EMT-Related Genes GALNT3 and OAS1 are Associated with Immune Cell Infiltration and Poor Prognosis in Lung Adenocarcinoma. Front Biosci (Landmark Ed). 2023;28(10):271. [PubMed ID: 37919050]. https://doi.org/10.31083/j.fbl2810271.
-
24.
Ke W, Zhang L, Dai Y. The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs). Thorac Cancer. 2020;11(4):835-9. [PubMed ID: 32043828]. [PubMed Central ID: PMC7113041]. https://doi.org/10.1111/1759-7714.13341.
-
25.
Qu Z, Sun F, Zhou J, Li L, Shapiro SD, Xiao G. Interleukin-6 Prevents the Initiation but Enhances the Progression of Lung Cancer. Cancer Res. 2015;75(16):3209-15. [PubMed ID: 26122841]. [PubMed Central ID: PMC4537823]. https://doi.org/10.1158/0008-5472.CAN-14-3042.